ArticleThe Journal of allergy and clinical immunology2019
COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.
Article in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- AI-based prediction of aspirin-exacerbated respiratory disease using nasal epithelial mRNA expression profiles.The journal of allergy and clinical immunology. Global · 2026Article
- Potential mechanisms and effects of AFB1-induced asthma: A comprehensive analysis based on network toxicology and molecular docking.PloS one · 2026Article
- Review
- Platelets engage mast cells in a bilateral IL-33-driven feed-forward loop.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention.Clinical reviews in allergy & immunology · 2025Review
- Beyond CCR7: dendritic cell migration in type 2 inflammation.Frontiers in immunology · 2025Review
- Cysteinyl Leukotrienes in Allergic Inflammation.Annual review of pathology · 2025Review
- Low Prostaglandin EJournal of clinical medicine · 2024Review
- Article
- Mast Cells in Aspirin-Exacerbated Respiratory Disease.Current allergy and asthma reports · 2024Review
- Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.Frontiers in allergy · 2024Review
- Aspirin-exacerbated respiratory disease: Updates in the era of biologics.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- FADS1-arachidonic acid axis enhances arachidonic acid metabolism by altering intestinal microecology in colorectal cancer.Nature communications · 2023Article
- Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021Review
- Pathomechanisms of AERD-Recent Advances.Frontiers in allergy · 2021Review
- The impact of endoscopic sinus surgery and aspirin desensitization on psychological burden in aspirin-exacerbated respiratory disease.World journal of otorhinolaryngology - head and neck surgery · 2020Article
- Epithelial cell function and remodeling in nasal polyposis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2020Review
- The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics.Journal of asthma and allergy · 2020Review
- Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.The Journal of allergy and clinical immunology · 2019Review
- Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.Current opinion in allergy and clinical immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundClassical FcεRI-induced mast cell (MC) activation causes synthesis of arachidonic acid (AA)-derived eicosanoids (leukotriene [LT] C
objectivesWe sought to determine the regulation and significance of MC-derived eicosanoids synthesized in response to IL-33, a cytokine critical to innate type 2 immunity.
methodsWe used an ex vivo model of mouse bone marrow-derived mast cells and an IL-33-dependent in vivo model of aspirin-exacerbated respiratory disease (AERD).
resultsIL-33 potently liberates AA and elicits LTC
conclusionsMC-intrinsic COX-1 amplifies IL-33-induced activation in the setting of innate type 2 immunity and might help explain the phenomenon of therapeutic desensitization to aspirin by nonselective COX inhibitors in patients with AERD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.